Reporter @WSJ covering biotech. From the "Apple Capital of the World"
Joined June 2020
- Tweets315
- Following1.4K
- Followers548
- Likes886
Xavier Martinez retweeted
To the scientific world, Moderna’s cancer vaccine’s results proved that a highly personalized, immune-targeting medication can work. To investors, it didn’t work well enough. W/ @xavierjohnm:
wsj.com/health/pharma/modern…
Xavier Martinez retweeted
EXCLUSIVE - Top RFK Jr. ally and adviser Calley Means has quit the Trump administration.
Means was frustrated by White House delays of some of Kennedy’s popular food policies and blamed others in the administration for allowing food companies and special interests to have too much sway, people familiar with the matter said.
One of them described him as “disillusioned.” wsj.com/politics/policy/call…
Xavier Martinez retweeted
#ESMO26: The embargo on LBA1, “INTerpath-001: Phase 3 study of the mRNA-based individualised neoantigen therapy intismeran autogene plus pembrolizumab versus pembrolizumab alone for adjuvant treatment of resected stage IIB-IV melanoma”, has been breached. As the data are now publicly available, ESMO has released the information contained in the abstract and has lifted the embargo on the full dataset.
Xavier Martinez retweeted
Medicaid data show some private-equity-backed chains billed far more hours than rivals. Companies say patient needs guide treatment. on.wsj.com/4z4imEu
Xavier Martinez retweeted
New notice from FDA on a“Fit-for-Purpose Rare Disease Framework Initiative” under review at OMB. Expect an upcoming request for information and public meeting on this:
Xavier Martinez retweeted
Drugmakers are targeting muscle preservation and fat loss as they build the next generation of weight-loss medications. on.wsj.com/3Vd54GL
Xavier Martinez retweeted
NEW with @LizzyLaw_: The Trump administration is rolling out a program aimed at getting Medicare to match drug prices in other countries for certain high-cost drugs
Pharma companies that cut deals with the admin expected to be exempt
wsj.com/health/pharma/trump-…
Xavier Martinez retweeted
NEW: A next-generation weight-loss drug from Eli Lilly, when combined with Zepbound, helped people lose substantially more weight than Zepbound alone, according to a new study wsj.com/health/pharma/lillys… via @WSJ
Xavier Martinez retweeted
NEW:
RFK Jr.'s efforts to revamp America’s food system have hit their biggest hurdle yet: The White House.
Trump aides are concerned Kennedy's ideas aren't feasible and could fuel litigation against food companies.
One of Kennedy’s top aides, Calley Means, accused White House officials of trying to block the definition to cater to special interests.
Inside the clashes over the future of American food:
With @jessenewman13 & @jdawsey1 🎁🔗wsj.com/politics/policy/rfk-…
Xavier Martinez retweeted
“There is no current evidence of a causal link between Tylenol and autism.”
- Dr. Heidi Overton, current White House staffer nominated to lead FDA
Xavier Martinez retweeted
Anthropic leaders have invested in a startup developing technology to detect airborne viruses, amid growing fears that AI could lead to new biological threats.
wsj.com/tech/ai/anthropic-le…
Xavier Martinez retweeted
The World is Running Out of Fuel
open.spotify.com/episode/5Vv…
Xavier Martinez retweeted
NEW: Pharmaceutical Companies Push Trump Administration to Protect China Deals wsj.com/health/pharma/pharma…
Xavier Martinez retweeted
Under Trump, crypto had the best opportunity it could hope for to enact legislation ushering it into mainstream finance.
It had enormous sway over the legislative process. And few people more so than Coinbase CEO @brian_armstrong.
So what happened?
wsj.com/finance/currencies/c…
Xavier Martinez retweeted
Make sure to read this deeply reported dive into Polymarket’s growth at any cost — featuring Drake, LeBron, wild Social Security number hacks, Adderall, and so many stolen debit cards
NEW: A story full of scoops big and small from @ceostroff and @byneilmehta.
> Polymarket removed one of its anti-money-laundering programs during a fraud attack, alarming some staff; CEO Shayne Coplan downplayed risks
> Persistent engineering glitches have cost some customers thousands
> Internal audio & text messages reveal Coplan’s management style
> Some current & former employees & investors are concerned Poly has prioritized growth at all costs
> Company is trying to course-correct; eyeing an IPO by the end of 2027
> Talks with Drake fell through; rapper name-dropped Poly in a song anyways; a market on the album saw suspicious trading
And more. Gift link below.
wsj.com/business/polymarkets…
Xavier Martinez retweeted
The little-discussed potential risk of popular diabetes and weight-loss drugs is on warning labels outside of the U.S. on.wsj.com/4iCirKc
